Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: JVN009
MIFTS: 39

Juvenile Pilocytic Astrocytoma

Categories: Cancer diseases, Eye diseases, Neuronal diseases, Rare diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Juvenile Pilocytic Astrocytoma

About this section

MalaCards integrated aliases for Juvenile Pilocytic Astrocytoma:

Name: Juvenile Pilocytic Astrocytoma 12 55 15 73

Classifications:

MalaCards categories:
Global: Cancer diseases Rare diseases
Anatomical: Neuronal diseases Eye diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:6811
MeSH 44 D001254
NCIt 50 C27081
UMLS 73 C0280783
Sources

Summaries for Juvenile Pilocytic Astrocytoma

About this section
MalaCards based summary : Juvenile Pilocytic Astrocytoma is related to pilocytic astrocytoma and glioma, and has symptoms including headache An important gene associated with Juvenile Pilocytic Astrocytoma is TIMP3 (TIMP Metallopeptidase Inhibitor 3), and among its related pathways/superpathways are ERK Signaling and PI3K-Akt signaling pathway. The drugs Procarbazine and Vincristine have been mentioned in the context of this disorder. Affiliated tissues include eye, brain and pineal, and related phenotypes are behavior/neurological and cellular

Sources

Related Diseases for Juvenile Pilocytic Astrocytoma

About this section

Diseases in the Pilocytic Astrocytoma family:

Juvenile Pilocytic Astrocytoma

Diseases related to Juvenile Pilocytic Astrocytoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 122)
# Related Disease Score Top Affiliating Genes
1 pilocytic astrocytoma 33.7 GFAP NF1 TIMP3
2 glioma 30.0 CDKN2A FGF2 NF1 TNC TP53
3 medulloblastoma 29.6 DDX3X ENO2 GFAP MAP2K1 TIMP3 TP53
4 oligodendroglioma 29.5 CDKN2A ENO2 GFAP MBP TP53
5 astrocytoma 10.9
6 ataxia, combined cerebellar and peripheral, with hearing loss and diabetes mellitus 10.3
7 childhood pilocytic astrocytoma 10.3 NF1 NTM
8 neurofibromatosis, type i 10.2
9 splenic diffuse red pulp small b-cell lymphoma 10.2 MAP2K1 TP53
10 frontal convexity meningioma 10.2 GFAP TP53
11 bladder squamous cell carcinoma 10.2 CDKN2A TP53
12 keratinizing squamous cell carcinoma 10.2 CDKN2A TP53
13 cerebral convexity meningioma 10.2 GFAP TP53
14 cellular ependymoma 10.2 GFAP TP53
15 protoplasmic astrocytoma 10.2 GFAP TP53
16 spitz nevus 10.2 CDKN2A TP53
17 meninges sarcoma 10.1 GFAP TP53
18 bladder carcinoma in situ 10.1 CDKN2A TP53
19 conventional leiomyosarcoma 10.1 CDKN2A NF1
20 vulva squamous cell carcinoma 10.1 CDKN2A TP53
21 scrotal carcinoma 10.1 CDKN2A TP53
22 mixed glioma 10.1 GFAP TP53
23 spinal cancer 10.1 GFAP TP53
24 ependymoblastoma 10.1 GFAP TP53
25 vulvar dystrophy 10.1 CDKN2A MBP
26 anaplastic oligodendroglioma 10.1 CDKN2A GFAP
27 actinic keratosis 10.1 CDKN2A TNC TP53
28 duodenal somatostatinoma 10.1 ENO2 NF1
29 skin melanoma 10.1 CDKN2A FGF2 TP53
30 vulvar disease 10.1 CDKN2A TP53
31 endometrial adenocarcinoma 10.1 CDKN2A FGF2 TP53
32 epithelioid malignant peripheral nerve sheath tumor 10.1 ENO2 NF1
33 cellular schwannoma 10.1 CDKN2A NF1 TP53
34 gliofibroma 10.1 GFAP NF1 TP53
35 malignant peripheral nerve sheath tumor 10.1 CDKN2A NF1 TP53
36 nasal cavity adenocarcinoma 10.1 CDKN2A TP53
37 chordoid glioma 10.1 GFAP TP53
38 li-fraumeni syndrome 10.1 CDKN2A NF1 TP53
39 glioma susceptibility 1 10.1
40 silver-russell syndrome 10.1
41 autism 10.1
42 leukemia, acute lymphoblastic 10.1
43 leukemia 10.1
44 autism spectrum disorder 10.1
45 lymphoma 10.1
46 sensorineural hearing loss 10.1
47 lymphocytic leukemia 10.1
48 amblyopia 10.1
49 arteriovenous malformation 10.1
50 ectropion 10.1

Graphical network of the top 20 diseases related to Juvenile Pilocytic Astrocytoma:



Diseases related to Juvenile Pilocytic Astrocytoma
Sources

Symptoms & Phenotypes for Juvenile Pilocytic Astrocytoma

About this section

UMLS symptoms related to Juvenile Pilocytic Astrocytoma:


headache

MGI Mouse Phenotypes related to Juvenile Pilocytic Astrocytoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.22 CDKN2A ENO2 FGF2 GFAP INSR MBP
2 cellular MP:0005384 10.21 CDKN2A DDX3X ENO2 FGF2 GFAP INSR
3 cardiovascular system MP:0005385 10.16 CDKN2A DDX3X FGF2 GFAP INSR MAP2K1
4 growth/size/body region MP:0005378 10.14 CDKN2A DDX3X ENO2 GFAP INSR MAP2K1
5 homeostasis/metabolism MP:0005376 10.1 CDKN2A DDX3X FGF2 GFAP INSR MAP2K1
6 mortality/aging MP:0010768 10 CDKN2A DDX3X FGF2 GFAP INSR MAP2K1
7 hearing/vestibular/ear MP:0005377 9.85 FGF2 MAP2K1 MBP NF1 TNC TP53
8 muscle MP:0005369 9.81 CDKN2A DDX3X FGF2 GFAP INSR NF1
9 nervous system MP:0003631 9.73 CDKN2A DDX3X ENO2 FGF2 GFAP INSR
10 vision/eye MP:0005391 9.28 CDKN2A FGF2 GFAP MAP2K1 MBP NF1
Sources

Drugs & Therapeutics for Juvenile Pilocytic Astrocytoma

About this section

Drugs for Juvenile Pilocytic Astrocytoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 157)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Procarbazine Approved, Investigational Phase 2, Phase 3 671-16-9 4915
2
Vincristine Approved, Investigational Phase 2, Phase 3,Phase 1 57-22-7, 2068-78-2 5978
3
Lomustine Approved, Investigational Phase 2, Phase 3 13010-47-4 3950
4
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
5
Donepezil Approved Phase 3,Phase 2 120014-06-4 3152
6
Dopamine Approved Phase 3,Early Phase 1,Not Applicable 51-61-6, 62-31-7 681
7
Histamine Approved, Investigational Phase 3 51-45-6, 75614-87-8 774
8
Cyproheptadine Approved Phase 3 129-03-3 2913
9
Methylphenidate Approved, Investigational Phase 3 113-45-1 4158
10 Pancreatic Polypeptide Investigational Phase 3,Phase 1 59763-91-6
11 Antineoplastic Agents, Alkylating Phase 2, Phase 3,Phase 1
12 Alkylating Agents Phase 2, Phase 3,Phase 1
13 Dermatologic Agents Phase 3,Phase 2,Phase 1
14 Antineoplastic Agents, Phytogenic Phase 2, Phase 3,Phase 1
15 Antimitotic Agents Phase 2, Phase 3,Phase 1
16 Cola Phase 3,Phase 1
17 Central Nervous System Depressants Phase 3
18 Adjuvants, Anesthesia Phase 3
19 Liver Extracts Phase 3,Phase 2,Phase 1
20 Anesthetics, Intravenous Phase 3
21 Analgesics, Opioid Phase 3
22 Peripheral Nervous System Agents Phase 3
23 Anesthetics, General Phase 3
24 Analgesics Phase 3
25 Narcotics Phase 3
26 Anesthetics Phase 3
27 Neurotransmitter Agents Phase 3,Phase 2,Early Phase 1,Not Applicable
28 Nootropic Agents Phase 3,Phase 2
29 Cholinergic Agents Phase 3,Phase 2
30 Cholinesterase Inhibitors Phase 3,Phase 2
31 Gastrointestinal Agents Phase 3,Phase 1,Not Applicable
32 Central Nervous System Stimulants Phase 3,Phase 2
33 Dopamine Agents Phase 3,Early Phase 1,Not Applicable
34 Serotonin Agents Phase 3
35 Anti-Allergic Agents Phase 3
36 Serotonin Antagonists Phase 3
37 Histamine H1 Antagonists Phase 3
38
Histamine Phosphate Phase 3 51-74-1 65513
39 Antipruritics Phase 3
40 Histamine Antagonists Phase 3
41 Dexmethylphenidate Hydrochloride Phase 3
42 Neurotransmitter Uptake Inhibitors Phase 3
43 Dopamine Uptake Inhibitors Phase 3
44
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202
45
Dacarbazine Approved, Investigational Phase 2,Phase 1 4342-03-4 5351166
46
Temozolomide Approved, Investigational Phase 2,Phase 1 85622-93-1 5394
47
Bevacizumab Approved, Investigational Phase 2,Phase 1 216974-75-3
48
Trioxsalen Approved Phase 2,Phase 1 3902-71-4 5585
49
Sirolimus Approved, Investigational Phase 1, Phase 2,Phase 2 53123-88-9 46835353 6436030 5284616
50
Everolimus Approved Phase 1, Phase 2,Phase 2 159351-69-6 6442177

Interventional clinical trials:

(show top 50) (show all 65)
# Name Status NCT ID Phase Drugs
1 Observation or Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Low-Grade Glioma Completed NCT00003375 Phase 2, Phase 3 lomustine;procarbazine hydrochloride;vincristine sulfate
2 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
3 Donepezil in Treating Patients Who Have Undergone Radiation Therapy for Brain Tumors Completed NCT00369785 Phase 3 donepezil hydrochloride;Placebo
4 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
5 Methylphenidate to Improve Quality of Life in Patients Undergoing Radiation Therapy for Brain Tumors Terminated NCT00031798 Phase 3 methylphenidate hydrochloride
6 Bevacizumab in Recurrent Grade II and III Glioma Unknown status NCT01164189 Phase 2 Temozolomide
7 Temozolomide in Treating Patients With Low-Grade Glioma Completed NCT00313729 Phase 2 temozolomide
8 Erlotinib and Temsirolimus in Treating Patients With Recurrent Malignant Glioma Completed NCT00112736 Phase 1, Phase 2 erlotinib;temsirolimus
9 Carmustine in Treating Adults With Recurrent Supratentorial Low-Grade Glioma Completed NCT00003467 Phase 2 carmustine;polifeprosan 20 with carmustine implant
10 Armodafinil in Treating Fatigue Caused By Radiation Therapy in Patients With Primary Brain Tumors Completed NCT01032200 Phase 2 Armodafinil
11 Temozolomide in Treating Patients With Progressive Low-Grade Glioma Completed NCT00003466 Phase 2 temozolomide
12 Tamoxifen, Carboplatin, and Topotecan in Treating Patients With CNS Metastases or Recurrent Brain or Spinal Cord Tumors Completed NCT00541138 Phase 2 carboplatin;tamoxifen citrate;topotecan hydrochloride
13 Temozolomide in Treating Patients With Recurrent Glioblastoma Multiforme or Other Malignant Glioma Completed NCT00498927 Phase 2 temozolomide
14 Magnetic Resonance Imaging and Magnetic Resonance Spectroscopic Imaging in Evaluating Patients Who Are Undergoing Treatment for Gliomas Completed NCT00274755 Phase 2 chemotherapy
15 Imatinib Mesylate in Treating Patients With Gliomas Completed NCT00039364 Phase 2 imatinib mesylate
16 Gefitinib in Treating Patients With Recurrent or Progressive CNS Tumors Completed NCT00025675 Phase 2 gefitinib
17 Phase II Studies Of Donepezil And Ginkgo Biloba In Irradiated Brain Tumor Completed NCT00070161 Phase 2 donepezil hydrochloride
18 Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Brain Cancers Completed NCT00002752 Phase 1, Phase 2
19 Imatinib Mesylate in Treating Patients With Recurrent Malignant Glioma or Meningioma Completed NCT00010049 Phase 1, Phase 2 imatinib mesylate
20 Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Brain Tumors Completed NCT00003461 Phase 1, Phase 2
21 Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors Completed NCT00002608 Phase 2 cisplatin;doxorubicin hydrochloride;tamoxifen citrate
22 Phase II Pegylated Interferon Recruiting NCT02343224 Phase 2 Pegylated interferon alpha-2b
23 A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas Recruiting NCT01837862 Phase 1, Phase 2 Mebendazole;Vincristine;Carboplatin;Temozolomide;Bevacizumab;Irinotecan
24 Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma Recruiting NCT01089101 Phase 1, Phase 2 Selumetinib
25 Phase II Pediatric Study With Dabrafenib in Combination With Trametinib in Patients With HGG and LGG Recruiting NCT02684058 Phase 2 dabrafenib;trametinib;Carboplatin with vincristine
26 Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma Active, not recruiting NCT01553149 Phase 2 Lenalidomide
27 Photodynamic Therapy (PDT) For Recurrent High Grade Gliomas Active, not recruiting NCT01966809 Phase 2 Photofrin photodynamic therapy.
28 Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Active, not recruiting NCT00553150 Phase 1, Phase 2 everolimus;temozolomide
29 Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer Active, not recruiting NCT00445965 Phase 2
30 Functional Magnetic Resonance Imaging and 1H-Nuclear Magnetic Resonance Spectroscopic Imaging in Treating Patients With Newly Diagnosed Brain Tumors Withdrawn NCT00005083 Phase 2
31 Photodynamic Therapy With Porfimer Sodium in Treating Patients With Refractory Brain Tumors Unknown status NCT00002647 Phase 1 verteporfin
32 Lonafarnib and Temozolomide in Treating Patients With Recurrent Primary Supratentorial Gliomas Unknown status NCT00083096 Phase 1 lonafarnib;temozolomide
33 RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma Completed NCT01119599 Phase 1 Gamma-Secretase Inhibitor RO4929097;Temozolomide
34 Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction Completed NCT00030498 Phase 1 erlotinib hydrochloride
35 Cellular Adoptive Immunotherapy Using Genetically Modified T-Lymphocytes in Treating Patients With Recurrent or Refractory High-Grade Malignant Glioma Completed NCT00730613 Phase 1
36 Sodium Stibogluconate and IFNa-2b Followed By CDDP, VLB and DTIC Treating Pts.With Advanced Melanoma or Other Cancers Completed NCT00498979 Phase 1 cisplatin;sodium stibogluconate;dacarbazine;vinblastine
37 Bortezomib and Temozolomide in Treating Patients With Brain Tumors or Other Solid Tumors That Have Not Responded to Treatment Completed NCT00544284 Phase 1 bortezomib;temozolomide
38 Erlotinib and Sirolimus in Treating Patients With Recurrent Malignant Glioma Completed NCT00509431 Phase 1 Erlotinib + Sirolimus
39 Tumor Tissue Analysis in Patients Receiving Imatinib Mesylate for Malignant Glioma Completed NCT00401024 Phase 1 imatinib mesylate
40 Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer Completed NCT00006368 Phase 1
41 BCX-1777 in Treating Patients With Refractory Cancer Completed NCT00073944 Phase 1 forodesine hydrochloride
42 Calcitriol Plus Carboplatin in Treating Patients With Advanced Solid Tumors Completed NCT00008086 Phase 1 carboplatin
43 Radiolabeled Monoclonal Antibody Therapy After Radiation Therapy in Treating Patients With Primary Brain Tumors Completed NCT00003484 Phase 1 carmustine;irinotecan hydrochloride
44 Thalidomide and Docetaxel in Treating Patients With Advanced Cancer Completed NCT00049296 Phase 1 docetaxel;thalidomide
45 MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma Completed NCT00020579 Phase 1 entinostat
46 Carboxyamidotriazole and Paclitaxel in Treating Patients With Advanced Solid Tumors or Refractory Lymphomas Completed NCT00019019 Phase 1 carboxyamidotriazole;paclitaxel
47 Monoclonal Antibody Therapy in Treating Patients With Leptomeningeal Cancer Completed NCT00003022 Phase 1
48 Imetelstat Sodium in Treating Young Patients With Refractory or Recurrent Solid Tumors or Lymphoma Completed NCT01273090 Phase 1 imetelstat sodium
49 Cognitive Biomarkers in Pediatric Brain Tumor Patients Recruiting NCT02914067 Phase 1
50 Using MRI-Guided Laser Heat Ablation to Induce Disruption of the Peritumoral Blood Brain Barrier to Enhance Delivery and Efficacy of Treatment of Pediatric Brain Tumors Recruiting NCT02372409 Phase 1 Doxorubicin;Etoposide

Search NIH Clinical Center for Juvenile Pilocytic Astrocytoma

Sources

Genetic Tests for Juvenile Pilocytic Astrocytoma

About this section
Sources

Anatomical Context for Juvenile Pilocytic Astrocytoma

About this section

MalaCards organs/tissues related to Juvenile Pilocytic Astrocytoma:

41
Eye, Brain, Pineal, Cerebellum, Liver, Spinal Cord, Cervix
Sources

Publications for Juvenile Pilocytic Astrocytoma

About this section

Articles related to Juvenile Pilocytic Astrocytoma:

(show all 46)
# Title Authors Year
1
Long-term outcomes of primarily metastatic juvenile pilocytic astrocytoma in children. ( 29125440 )
2018
2
Circulating serum oncologic miRNA in pediatric juvenile pilocytic astrocytoma patients predicts mural nodule volume. ( 29911246 )
2018
3
Resection of a Pediatric Thalamic Juvenile Pilocytic Astrocytoma with Whole Brain Tractography. ( 29234572 )
2017
4
Using urinary bFGF and TIMP3 levels to predict the presence of juvenile pilocytic astrocytoma and establish a distinct biomarker signature. ( 27314542 )
2016
5
Spontaneous aneurysmal subarachnoid haemorrhage in a child with multiply recurrent posterior fossa juvenile pilocytic astrocytoma. ( 27927709 )
2016
6
Preoperative Presentation of a Variant of Cerebellar Mutism Syndrome in a Young Boy With Juvenile Pilocytic Astrocytoma. ( 26145481 )
2015
7
Hodgkin's lymphoma in an adolescent previously treated with surgical resection of third ventricular juvenile pilocytic astrocytoma. ( 26113587 )
2015
8
Peduncular Hallucinosis as First Presentation of Juvenile Pilocytic Astrocytoma. ( 26548431 )
2015
9
Intracranial organizing hematoma with papillary endothelial hyperplasia features after resection and involved field radiotherapy for cerebellar juvenile pilocytic astrocytoma. ( 24456989 )
2014
10
A case of central precocious puberty due to concomitant hypothalamic hamartoma and juvenile pilocytic astrocytoma. ( 25241615 )
2014
11
An unbalanced translocation involving loss of 10q26.2 and gain of 11q25 in a pedigree with autism spectrum disorder and cerebellar juvenile pilocytic astrocytoma. ( 23495067 )
2013
12
Secondary glioblastoma multiforme in a child with disseminated juvenile pilocytic astrocytoma. ( 23227384 )
2012
13
Retrocochlear hearing loss in infants: a case study of juvenile pilocytic astrocytoma. ( 22642312 )
2012
14
Juvenile pilocytic astrocytoma in association with arteriovenous malformation. ( 22681727 )
2012
15
Transformation of juvenile pilocytic astrocytoma to anaplastic pilocytic astrocytoma in patients with neurofibromatosis type I. ( 21572348 )
2011
16
Picture of the month--quiz case. Lisch nodules, ectropion uveae, and optic pathway glioma (juvenile pilocytic astrocytoma) due to neurofibromatosis type 1. ( 20439802 )
2010
17
Medulloblastoma and juvenile pilocytic astrocytoma presenting as synchronous primary brain tumors in a child: case report. ( 20121362 )
2010
18
Role of diffusion tensor imaging in resection of thalamic juvenile pilocytic astrocytoma. ( 19951034 )
2009
19
Long-term functional outcome of surgical treatment of juvenile pilocytic astrocytoma of the cerebellum in children. ( 19418058 )
2009
20
Supratentorial juvenile pilocytic astrocytoma in a young adult with Silver-Russell syndrome. ( 18661310 )
2008
21
Steroid responsive fluctuating sensorineural hearing loss due to juvenile pilocytic astrocytoma involving the cerebellopontine angle. ( 18255162 )
2008
22
Excision of juvenile pilocytic astrocytoma of the midbrain after radiotherapy. ( 16902345 )
2006
23
Gefitinib is effective against juvenile pilocytic astrocytoma in vitro. ( 16206208 )
2006
24
Juvenile pilocytic astrocytoma of the brainstem in children. ( 16206964 )
2004
25
Juvenile pilocytic astrocytoma presenting with subarachnoid hemorrhage. Case report and review of the literature. ( 15287467 )
2004
26
Juvenile pilocytic astrocytoma 'pilomyxoid variant' with spinal metastases. ( 15261239 )
2004
27
Oligodendroglioma and juvenile pilocytic astrocytoma presenting as synchronous primary brain tumors. Case report with histological and molecular differentiation of the tumors and review of the literature. ( 15070126 )
2004
28
Successful high-dose chemotherapy for widespread neuroaxis dissemination of an optico-hypothalamic juvenile pilocytic astrocytoma in an infant: a case report. ( 12777080 )
2003
29
Juvenile pilocytic astrocytoma. ( 12880155 )
2003
30
Spontaneous cerebellar hemorrhage due to a juvenile pilocytic astrocytoma: case report and review of the literature. ( 11423772 )
2001
31
Case report: Hemispheric juvenile pilocytic astrocytoma with extreme exophytic growth. ( 11384146 )
2001
32
Concurrent acute lymphoblastic leukemia and juvenile pilocytic astrocytoma in a pediatric patient. ( 11037859 )
2000
33
Multicentric juvenile pilocytic astrocytoma occurring primarily in the trigone of the lateral ventricle. ( 10502010 )
1999
34
Tracer transport and metabolism in a patient with juvenile pilocytic astrocytoma. A PET study. ( 9524106 )
1998
35
Hypothalamic juvenile pilocytic astrocytoma presenting with intracerebral hemorrhage. ( 9872037 )
1998
36
Juvenile pilocytic astrocytoma masquerading as amblyopia. ( 9152078 )
1997
37
Normal evoked otoacoustic emissions with a profound hearing loss due to a juvenile pilocytic astrocytoma. ( 8841714 )
1996
38
Treatment options and prognosis for multicentric juvenile pilocytic astrocytoma. ( 8207524 )
1994
39
Leptomeningeal dissemination of juvenile pilocytic astrocytoma: case report. ( 8165503 )
1994
40
Radiation therapy for juvenile pilocytic astrocytoma of the pituitary stalk. Case report. ( 1607955 )
1992
41
Metastatic juvenile pilocytic astrocytoma. Case report. ( 1941128 )
1991
42
Juvenile pilocytic astrocytoma of the optic nerve diagnosed by fine needle aspiration biopsy. ( 3376707 )
1988
43
Treatment results of juvenile pilocytic astrocytoma. ( 3392563 )
1988
44
Juvenile pilocytic astrocytoma of the cerebrum in adults. A distinctive neoplasm with favorable prognosis. ( 4020465 )
1985
45
Juvenile pilocytic astrocytoma of the pineal region: report of a case. ( 7104961 )
1982
46
Isolated trochlear nerve palsy secondary to a juvenile pilocytic astrocytoma. ( 6226694 )
1982
Sources

Variations for Juvenile Pilocytic Astrocytoma

About this section
Sources

Expression for Juvenile Pilocytic Astrocytoma

About this section
Search GEO for disease gene expression data for Juvenile Pilocytic Astrocytoma.
Sources

Pathways for Juvenile Pilocytic Astrocytoma

About this section

Pathways related to Juvenile Pilocytic Astrocytoma according to GeneCards Suite gene sharing:

(show all 19)
# Super pathways Score Top Affiliating Genes
1
ERK Signaling 64
Show member pathways
 13.63 CDKN2A FGF2 GFAP INSR MAP2K1 NF1
2
PI3K-Akt signaling pathway 37
Show member pathways
 12.82 FGF2 INSR MAP2K1 TNC TP53
3
Glioma 37
Show member pathways
 12.5 CDKN2A FGF2 MAP2K1 NF1 TP53
4
MAPK signaling pathway 37 1
12.47 FGF2 INSR MAP2K1 NF1 TP53
5
Neuroscience 4
12.19 ENO2 GFAP MBP NF1 TNC
6
MicroRNAs in cancer 37
12.03 CDKN2A MAP2K1 TIMP3 TNC TP53
7
G-protein signaling Ras family GTPases in kinase cascades (scheme) 22
Show member pathways
 12.01 MAP2K1 MBP TIMP3 TP53
8
Proteoglycans in cancer 37
11.93 FGF2 MAP2K1 TIMP3 TP53
9
Spinal Cord Injury 1
11.83 GFAP MBP TP53
10
DNA Damage Response (only ATM dependent) 1
11.8 CDKN2A INSR TP53
11
Senescence and Autophagy in Cancer 1
11.76 CDKN2A MAP2K1 TP53
12
Neural Crest Differentiation 1
11.72 FGF2 GFAP MBP
13
HIF-1 signaling pathway 37
11.7 ENO2 INSR MAP2K1
14
Angiogenesis (CST) 4
11.62 FGF2 TIMP3 TNC
15
G-protein signaling_RhoA regulation pathway 22
11.54 FGF2 INSR MAP2K1 TIMP3
16
Bladder cancer 37 1
11.52 CDKN2A MAP2K1 TP53
17
MECP2 and Associated Rett Syndrome 1
11.34 FGF2 MBP NF1
18
Glioblastoma Multiforme 64
10.97 CDKN2A MAP2K1 NF1 TP53
19
G-protein signaling_Rap2B regulation pathway 22
10.34 FGF2 GFAP INSR MAP2K1 TIMP3 TNC
Sources

GO Terms for Juvenile Pilocytic Astrocytoma

About this section

Biological processes related to Juvenile Pilocytic Astrocytoma according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription, DNA-templated GO:0045893 9.88 CDKN2A FGF2 INSR MAP2K1 TP53
2 positive regulation of apoptotic process GO:0043065 9.83 CDKN2A DDX3X NF1 TP53
3 negative regulation of cell growth GO:0030308 9.69 CDKN2A DDX3X TP53
4 activation of MAPK activity GO:0000187 9.67 FGF2 INSR MAP2K1
5 wound healing GO:0042060 9.63 FGF2 NF1 TNC
6 MAPK cascade GO:0000165 9.62 FGF2 MAP2K1 MBP NF1
7 extracellular matrix organization GO:0030198 9.56 FGF2 GFAP NF1 TNC
8 positive regulation of gene expression GO:0010628 9.55 CDKN2A DDX3X MAP2K1 TNC TP53
9 positive regulation of glycolytic process GO:0045821 9.54 INSR ZBTB20
10 replicative senescence GO:0090399 9.43 CDKN2A TP53
11 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.4 MAP2K1 TP53
12 Bergmann glial cell differentiation GO:0060020 9.37 GFAP MAP2K1
13 neuron recognition GO:0008038 8.96 NTM OPCML
14 Ras protein signal transduction GO:0007265 8.92 CDKN2A FGF2 NF1 TP53

Molecular functions related to Juvenile Pilocytic Astrocytoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.5 CD276 CDKN2A DDX3X ENO2 FGF2 GFAP
2 transcription factor binding GO:0008134 9.46 CDKN2A DDX3X MLX TP53
3 protease binding GO:0002020 9.13 MBP TIMP3 TP53
Sources

Sources for Juvenile Pilocytic Astrocytoma

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....